Bausch Health Companies (BHC) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Bausch Health Companies (BHC) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Bausch Health Companies | 2.57 Bn | 734.50 Mn | 2.10 Bn | 103.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.13% |
| Mar 31, 2026 | -1,563.95% |
| Dec 31, 2025 | -205.10% |
| Sep 30, 2025 | 296.74% |
| Jun 30, 2025 | 12,900.00% |
| Mar 31, 2025 | -11.69% |
| Dec 31, 2024 | 308.51% |
| Sep 30, 2024 | 75.92% |
| Jun 30, 2024 | -103.70% |
| Mar 31, 2024 | 63.16% |
| Dec 31, 2023 | 88.54% |
| Sep 30, 2023 | -194.79% |
| Jun 30, 2023 | 119.42% |
| Mar 31, 2023 | -216.67% |
| Dec 31, 2022 | -669.44% |
| Sep 30, 2022 | 110.99% |
| Jun 30, 2022 | 76.56% |
| Mar 31, 2022 | 89.13% |
| Dec 31, 2021 | 147.06% |
| Sep 30, 2021 | 169.01% |